Navigation Links
Neuralstem chief scientific officer to take part in World Stem Cell Summit plenary session
Date:10/1/2010

Neuralstem, Inc. (NYSE Amex: CUR) announced that the Chairman of its Board of Directors and Chief Scientific Officer, Dr. Karl Johe, PhD, will take part in a plenary discussion entitled, Current and Future Clinical Trials and Stem Cell Therapies, at the World Stem Cell Summit on October 5, in Detroit, MI (http://www.worldstemcellsummit.com/summit-agenda). Dr. Johe is the creator of Neuralstems neural stem cell technology.

The panel will be moderated by Dr. Eva Feldman, PhD, MD, Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System, and includes as well Dr. Jonathan Glass, MD, Professor of Neurology & Director Emory ALS Center Emory University, and Dr. Nicholas Boulis, MD, Assistant Professor Neurosurgery Emory University.

Neuralstem is currently sponsoring a Phase I trial of its spinal cord stem cells in patients with amyotrophic lateral sclerosis (ALS or Lou Gehrigs disease) at the ALS Center at Emory University, in Atlanta, GA. Dr. Feldman is the Principal Investigator, Dr. Glass is the Site Principal Investigator and Dr. Boulis is the Co-Investigator and Neurosurgeon.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in a Phase I safety clinical trial for Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's disease. In addition to ALS, the company is targeting major central nervous system diseases, including traumatic spinal cord injury, ischemic spastic paraplegia, and Huntington's disease. The company has also submitted an IND application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Through its proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions. The company plans to initiate clinical trials to treat Alzheimer's disease and major depression with its lead compound, as well as pursue additional indications, including traumatic brain injury, posttraumatic stress syndrome, stroke and schizophrenia.


'/>"/>

Contact: Deanne Eagle
deanneeagle@gmail.com
917-837-5866
Neuralstem, Inc.
Source:Eurekalert

Related medicine news :

1. Neuralstem stem cells survive and differentiate into neurons in rats with stroke
2. Neuralstem files FDA application for first chronic spinal cord injury stem cell trial
3. Neuralstem updates clinical trial progress
4. National Institute of General Medical Sciences chief wins prestigious public service award
5. FDA Chief Says More Egg Recalls Possible
6. Spectrum Surgical Instruments Appoints President, Chief Operating Officer
7. DKI Direct Appoints Greg Lewis as Chief Marketing Officer
8. BioNeutral Chief Scientist Dr. Andy Kielbania Appointed to Steri - 7 for Expanded Role
9. Steri -7 Appoints BioNeutral Group Inc. Chief Scientist Dr. Andy Kielbania for Expanded Role
10. Former NIH Chief Joins Children's National Medical Center
11. Martek Biosciences Chief Scientific Officer, Dr. Norman Salem, 2010 Recipient of Alex Leaf Distinguished Scientist Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... The Masters of Science in ... leaders with decades of experience who remain current practitioners in the field. With ... there is a renewed demand for versatile, data-driven leadership.The American University’s MS in ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... Living (IHCA/INCAL), will serve as a healthcare industry expert at the 2017 Sector ... discussion, moderated by Inside Indiana Business host Gerry Dick, will feature an employer ...
(Date:1/23/2017)... Oregon (PRWEB) , ... January 23, 2017 , ... ... announced today it has earned organic certification under the USDA National Organic Program ... USDA Organic Certification process, we have established organic production and handling systems to ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... in partnership with the American Society of Anesthesiologists® (ASA®), the Foundation for ... American Academy of Orthopaedic Surgeons (AAOS) and the Cigna Foundation, encourages proposals ...
(Date:1/23/2017)... ... 2017 , ... “Crossing the Bar”: a moving and eloquent drama depicting ... the Bar” is the creation of published author, Charlotte Hotte, a North Carolina native, ... the inspiration of the book to her sister, Denise, wishes to acknowledge her savior, ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... Calif. , Jan. 23, 2017  Based ... market, Frost & Sullivan recognizes Ansell, a global ... Frost & Sullivan Company of the Year Award. ... approach, and a wide global footprint have placed ... the hand protection market. The Company,s established product ...
(Date:1/23/2017)... , Jan. 23, 2017 MouthWatch LLC announced ... was ranked as the best intraoral camera on DentalCompare,s ... the #2 spot overall. The #1 product was the ... the MouthWatch intraoral camera was "…incredibly popular because it is ... camera has a small sticker price, it doesn,t sacrifice quality ...
(Date:1/23/2017)... 2017 Direct-to-consumer digital ... sold and 65% increase in consumable sales, quarter-over-quarter ... (NASDAQ: DRIO ), a leader in digital ... the Dario™ Blood Glucose Monitoring System, an all-in-one diabetes ... app-based and minimally invasive smart diabetes management solution. ...
Breaking Medicine Technology: